Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Neptune Technologies & Bioressources' Sherbrooke Plant To Resume Production

RELATED NEWS
Trade NEPT now with 

Neptune Technologies & Bioressources Inc. (NEPT: Quote, NTB.TO) announced that its Sherbrooke, Quebec, Canada production facility has received all required operating permits and production will now resume.

The company noted that production will commence gradually and the Corporation anticipates a ramp up period of around 90 days before reaching production capacity of approximately 150 metric tons of krill oil annually. The plant will focus on producing Neptune's premium krill oil, NKO, the original krill oil, with the highest concentration of omega-3 phospholipids in the industry and strong brand awareness.

Later this year, Neptune will also make available three new condition-specific formulations, including: NKOBEAT: supports heart health and blood circulation; NKO FLEX: supports bone and joint health; NKO FOCUS: supports brain and vision health.

Click here to receive FREE breaking news email alerts for Neptune Technologies & Bioresources, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.